Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC et al., (2015) 473 F.T.R. 1 (FC)

This document cites

• Eli Lilly Canada Inc. v. Apotex Inc. et al., 2009 FC 320
• Sanofi-Synthelabo Canada Inc. et al. v. Apotex Inc. et al., (2008) 381 N.R. 125 (SCC)
• AstraZeneca Canada Inc. et al. v. Mylan Pharmaceuticals ULC et al., (2012) 432 N.R. 292 (FCA)
• Pfizer Canada Inc. et al. v. Novopharm Ltd. et al., (2012) 436 N.R. 299 (SCC)
• Fournier Pharma Inc. et al. v. Canada (Minister of Health) et al., (2012) 413 F.T.R. 277 (FC)



See all quotations

• Pfizer Canada Inc. et al. v. Mylan Pharmaceuticals ULC et al., (2012) 430 N.R. 326 (FCA)
• Eli Lilly Canada Inc. v. Apotex Inc. et al., 2007 FC 455
• AstraZeneca Canada Inc. et al. v. Pharmascience Inc. et al., (2014) 460 N.R. 343 (FCA)
• Bayer AG et al. v. Novopharm Ltd. et al., 2006 FC 379
• R. v. Evans (C.D.), (1993) 145 A.R. 81 (SCC)
• Whirlpool Corp. et al. v. Camco Inc. et al., (2000) 263 N.R. 88 (SCC)
• Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al., (2007) 366 N.R. 347 (FCA)
• Laboratoires Servier et al. v. Apotex Inc. et al., (2008) 332 F.T.R. 193 (FC)
• Apotex Inc. v. Bristol-Myers Squibb Co. et al., 2007 FCA 379
• Hoffmann-La Roche Ltd. v. Apotex Inc. et al., (2011) 394 F.T.R. 142 (FC)
• Free World Trust v. Électro Santé Inc. et al., (2000) 263 N.R. 150 (SCC)
• Eurocopter v. Bell Helicopter Textron Canada Ltd. et al., (2013) 449 N.R. 111 (FCA)
• Teva Canada Ltd. v. Novartis AG, (2013) 428 F.T.R. 1 (FC)
• Pfizer Canada Inc. et al. v. Apotex Inc. et al., (2007) 319 F.T.R. 48 (FC)
• Armstrong v. Canada (Attorney General), [2005] F.T.R. Uned. 613 (FC)
• R. v. Evans (C.D.), (1993) 158 N.R. 278 (SCC)
• Abbott Laboratories et al. v. Canada (Minister of Health) et al., (2005) 281 F.T.R. 74 (FC)
• Pfizer Canada Inc. et al. v. Apotex Inc. et al., (2014) 465 N.R. 306 (FCA)
• Schering-Plough Canada Inc. et al. v. Pharmascience Inc. et al., 2009 FC 1128
• Laboratoires Servier et al. v. Apotex Inc. et al., (2009) 392 N.R. 96 (FCA)
• Pfizer Canada Inc. et al. v. Apotex Inc. et al., (2014) 451 F.T.R. 158 (FC)
• AstraZeneca Canada Inc. et al. v. Mylan Pharmaceuticals ULC et al., 2011 FC 1023
• Bayer Inc. et al. v. Apotex Inc. et al., (2014) 454 F.T.R. 48 (FC)
• Alcon Canada Inc. et al. v. Cobalt Pharmaceuticals Co. et al., (2014) 454 F.T.R. 265 (FC)
• Abbott Laboratories et al. v. Canada (Minister of Health) et al., (2007) 361 N.R. 308 (FCA)
• Novo Nordisk Canada Inc. et al. v. Cobalt Pharmaceuticals Inc. et al., 2010 FC 746
• Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al., 2011 FCA 236
• Apotex Inc. and Novopharm Ltd. v. Wellcome Foundation Ltd., (2002) 296 N.R. 130 (SCC)
• Aventis Pharma Inc. v. Pharmascience, 2006 FCA 229
• Consolboard Inc. v. MacMillan Bloedel (Saskatchewan) Ltd., (1981) 35 N.R. 390 (SCC)